The serotonin syndrome and its treatment
PK Gillman - Journal of Psychopharmacology, 1999 - journals.sagepub.com
Serotonin syndrome is caused by drug induced excess of intrasynaptic 5-hydroxytryptamine.
The clinical manifestations are mediated by the action of 5-hydroxytryptamine on various …
The clinical manifestations are mediated by the action of 5-hydroxytryptamine on various …
Serotonin syndrome: a clinical update
KC Mills - Critical care clinics, 1997 - Elsevier
Serotonin syndrome (SS) is an important drug-related complication of psychopharmacologic
therapy for major depression, bipolar affective disorder, obsessive-compulsive disorder …
therapy for major depression, bipolar affective disorder, obsessive-compulsive disorder …
Selective serotonin reuptake inhibitor-induced serotonin syndrome
R Lane, D Baldwin - Journal of clinical psychopharmacology, 1997 - journals.lww.com
The selective pharmacology of the selective serotonin reuptake inhibitors (SSRIs) results in
a lower potential for pharmacodynamic drug interactions relative to other antidepressants …
a lower potential for pharmacodynamic drug interactions relative to other antidepressants …
Serotonin syndrome: history and risk
PK Gillman - Fundamental & clinical pharmacology, 1998 - Wiley Online Library
This review focuses on the history of investigations into the behavioural reaction resulting
from excess stimulation of postsynaptic 5‐hydroxytryptamine receptors and the relative risk …
from excess stimulation of postsynaptic 5‐hydroxytryptamine receptors and the relative risk …
Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review
P Ken Gillman - Headache: The Journal of Head and Face …, 2010 - Wiley Online Library
(Headache 2010; 50: 264‐272) The US Food and Drug Administration (FDA) have
suggested that fatal serotonin syndrome (SS) is possible with selective serotonin reuptake …
suggested that fatal serotonin syndrome (SS) is possible with selective serotonin reuptake …
Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of …
A Gobert, JM Rivet, L Cistarelli, C Melon, MJ Millan - Neuroscience, 1999 - Elsevier
The serotonin1A receptor partial agonist, buspirone, also displays antagonist properties at
D2 receptors and is metabolized to the α2-adrenergic receptor antagonist, 1-(2-pyrimidinyl …
D2 receptors and is metabolized to the α2-adrenergic receptor antagonist, 1-(2-pyrimidinyl …
Buspirone augmentation of antidepressant therapy
EC Dimitriou, CE Dimitriou - Journal of clinical …, 1998 - journals.lww.com
Thirty outpatients meeting DSM-III-R or DSM-IV criteria for major depression, single or
recurrent episode, and failing to respond to an adequate trial of an antidepressant (> 6 …
recurrent episode, and failing to respond to an adequate trial of an antidepressant (> 6 …
Buspirone: an updated review of its clinical pharmacology and therapeutic applications
B Fulton, RN Brogden - Cns Drugs, 1997 - Springer
Synopsis Buspirone is an anxiolytic agent from the azapirone class of compounds. It differs
structurally and pharmacologically from the benzodiazepines. Although the exact anxiolytic …
structurally and pharmacologically from the benzodiazepines. Although the exact anxiolytic …
[PDF][PDF] Скорая медицинская помощь
СФ Багненко, МШ Хубутия… - Национальное …, 2015 - static-sl.insales.ru
Основные принципы СЛР были опубликованы в работах ВА Неговского, P. Safar и
других еще в 1954–1960 гг. Они обосновали эффективность закрытого массажа …
других еще в 1954–1960 гг. Они обосновали эффективность закрытого массажа …
[图书][B] Neuroleptic malignant syndrome and related conditions
SC Mann, SN Caroff, PE Keck, A Lazarus - 2003 - psycnet.apa.org
Abstract Neuroleptic Malignant Syndrome and Related Conditions is an important tool for
clinicians, outlining a framework for understanding, diagnosing, treating, and preventing …
clinicians, outlining a framework for understanding, diagnosing, treating, and preventing …